Top Markets
Coin of the day
Valerio Therapeutics S.A. Valerio Therapeutics S.A.

Valerio Therapeutics S.A.

ALVIO
株式のランク #14050
Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A.... Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A. (known as Onxeo SA until June 2023) is a clinical-stage biotechnology company dedicated to the global research and development of oncology treatments. Their focus is on targeting the DNA repair processes crucial for tumor survival. The company's offerings include Beleodaq, an approved medication for peripheral T-cell lymphoma. Their development pipeline features AsiDNA, which is progressing through Phase 1 clinical trials for metastatic melanoma and is also being evaluated for relapsed ovarian cancer through a research collaboration with Gustave Roussy. Furthermore, Valerio Therapeutics is advancing OX401, a preclinical program targeting DNA damage response and immuno-oncology, along with its proprietary platON decoy oligonucleotide platform. The firm also holds a licensing agreement with Acrotech Biopharma LLC.
株価
$0.88012714
最終同期: 2026-08-31
時価総額
$439.58M
変化(1日)
-4.01%
変化(1年)
1,131.97%
FR
取引 Valerio Therapeutics S.A. (ALVIO)

カテゴリー

Valerio Therapeutics S.A.(ALVIO)のP/B比率
2026 時点のP/B比率 TTM: 0
Valerio Therapeutics S.A. の最新の財務報告および株価によると、現在のP/B比率(TTM)は 0 です。2026 年末時点でのP/B比率は 0 でした。
Valerio Therapeutics S.A. の P/B 比率の履歴(2026 ~ 2026)
各年末時点のP/B比率
P/B比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/B比率
企業 P/B比率 P/B比率の差
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
3.7087 -
US
- -
CH